BACKGROUND: Sleep disruption and fatigue are common in Multiple Sclerosis (MS). Melatonin is one of the major regulators of sleep-wake cycle. The role of melatonin in MS-related sleep disturbances and fatigue as well as the interaction between melatonin and Interferon beta (IFN-β) treatment were the subject of this study. OBJECTIVE: To assess the influence of IFN-β treatment on melatonin secretion, fatigue and sleep characteristics in patients with MS. METHODS: 13 MS patients and 12 healthy controls participated. Fatigue was evaluated using the Fatigue Impact Scale (FIS), sleep was assessed by actigraphy and day/night levels of 6-sulphatoxy-melatonin (6-SMT) in urine were determined using a highly specific ELISA assay. RESULTS: Naïve MS patients demonstrated significantly decreased levels of 6-SMT and disrupted circadian regulation of its secretion, which were increased with IFN-β treatment, in association with improved fatigue. Sleep Efficiency was significantly lower in the MS group compared to controls. CONCLUSION: Our findings suggest dysregulation of Melatonin secretion in MS, which may be influenced by IFN-β treatment. The results call for further characterization of the role of neuro-hormones such as melatonin in MS, and their cross-regulation with immune-mediators.
BACKGROUND: Sleep disruption and fatigue are common in Multiple Sclerosis (MS). Melatonin is one of the major regulators of sleep-wake cycle. The role of melatonin in MS-related sleep disturbances and fatigue as well as the interaction between melatonin and Interferon beta (IFN-β) treatment were the subject of this study. OBJECTIVE: To assess the influence of IFN-β treatment on melatonin secretion, fatigue and sleep characteristics in patients with MS. METHODS: 13 MS patients and 12 healthy controls participated. Fatigue was evaluated using the Fatigue Impact Scale (FIS), sleep was assessed by actigraphy and day/night levels of 6-sulphatoxy-melatonin (6-SMT) in urine were determined using a highly specific ELISA assay. RESULTS: Naïve MS patients demonstrated significantly decreased levels of 6-SMT and disrupted circadian regulation of its secretion, which were increased with IFN-β treatment, in association with improved fatigue. Sleep Efficiency was significantly lower in the MS group compared to controls. CONCLUSION: Our findings suggest dysregulation of Melatonin secretion in MS, which may be influenced by IFN-β treatment. The results call for further characterization of the role of neuro-hormones such as melatonin in MS, and their cross-regulation with immune-mediators.
Authors: J Singh; M Cerghet; L M Poisson; I Datta; K Labuzek; H Suhail; R Rattan; Shailendra Giri Journal: J Neuroimmune Pharmacol Date: 2018-10-12 Impact factor: 4.147
Authors: Nancy S Redeker; Samantha Conley; George Anderson; John Cline; Laura Andrews; Vahid Mohsenin; Daniel Jacoby; Sangchoon Jeon Journal: Behav Sleep Med Date: 2018-11-21 Impact factor: 2.964
Authors: Donald J Fogelberg; Abbey J Hughes; Michael V Vitiello; Jeanne M Hoffman; Dagmar Amtmann Journal: J Clin Sleep Med Date: 2016-05-15 Impact factor: 4.062